JP7511576B2 - Ｒｅｔを結合するヒト抗体およびその使用方法 - Google Patents

Ｒｅｔを結合するヒト抗体およびその使用方法 Download PDF

Info

Publication number
JP7511576B2
JP7511576B2 JP2021559435A JP2021559435A JP7511576B2 JP 7511576 B2 JP7511576 B2 JP 7511576B2 JP 2021559435 A JP2021559435 A JP 2021559435A JP 2021559435 A JP2021559435 A JP 2021559435A JP 7511576 B2 JP7511576 B2 JP 7511576B2
Authority
JP
Japan
Prior art keywords
ret
antibody
antigen
antibodies
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527373A5 (https=
JP2022527373A (ja
Inventor
クリストファー ダリー，
ギャビン サーストン，
ニコラス パパドプロス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022527373A publication Critical patent/JP2022527373A/ja
Publication of JP2022527373A5 publication Critical patent/JP2022527373A5/ja
Priority to JP2024002528A priority Critical patent/JP7688175B2/ja
Application granted granted Critical
Publication of JP7511576B2 publication Critical patent/JP7511576B2/ja
Priority to JP2025085725A priority patent/JP2025113406A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021559435A 2019-04-10 2020-04-09 Ｒｅｔを結合するヒト抗体およびその使用方法 Active JP7511576B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024002528A JP7688175B2 (ja) 2019-04-10 2024-01-11 Ｒｅｔを結合するヒト抗体およびその使用方法
JP2025085725A JP2025113406A (ja) 2019-04-10 2025-05-22 Ｒｅｔを結合するヒト抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832218P 2019-04-10 2019-04-10
US62/832,218 2019-04-10
PCT/US2020/027554 WO2020210551A1 (en) 2019-04-10 2020-04-09 Human antibodies that bind ret and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002528A Division JP7688175B2 (ja) 2019-04-10 2024-01-11 Ｒｅｔを結合するヒト抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022527373A JP2022527373A (ja) 2022-06-01
JP2022527373A5 JP2022527373A5 (https=) 2023-01-10
JP7511576B2 true JP7511576B2 (ja) 2024-07-05

Family

ID=70554175

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021559435A Active JP7511576B2 (ja) 2019-04-10 2020-04-09 Ｒｅｔを結合するヒト抗体およびその使用方法
JP2024002528A Active JP7688175B2 (ja) 2019-04-10 2024-01-11 Ｒｅｔを結合するヒト抗体およびその使用方法
JP2025085725A Pending JP2025113406A (ja) 2019-04-10 2025-05-22 Ｒｅｔを結合するヒト抗体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024002528A Active JP7688175B2 (ja) 2019-04-10 2024-01-11 Ｒｅｔを結合するヒト抗体およびその使用方法
JP2025085725A Pending JP2025113406A (ja) 2019-04-10 2025-05-22 Ｒｅｔを結合するヒト抗体およびその使用方法

Country Status (11)

Country Link
US (1) US20220185900A1 (https=)
EP (1) EP3953390A1 (https=)
JP (3) JP7511576B2 (https=)
KR (1) KR20210150509A (https=)
CN (1) CN113993898B (https=)
AU (1) AU2020270966B2 (https=)
CA (1) CA3134258A1 (https=)
IL (1) IL287067A (https=)
MA (1) MA55615A (https=)
MX (1) MX2021012335A (https=)
WO (1) WO2020210551A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
BR112023015561A2 (pt) 2021-02-03 2023-11-14 Univ Minnesota Compostos imunoestimuiladores e conjugados
US20250154236A1 (en) * 2022-01-31 2025-05-15 Glaxosmithkline Intellectual Property (No. 3) Limited Prevention and treatment of headaches
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
JP2025525904A (ja) 2022-08-03 2025-08-07 シージェン インコーポレイテッド 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
TW202541841A (zh) * 2023-12-20 2025-11-01 美商黛安瑟斯醫療運營公司 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049624A1 (ja) 2005-10-24 2007-05-03 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
JP2008546716A (ja) 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ＧＦＲα３抗体
JP2015532647A (ja) 2012-08-22 2015-11-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＧＦＲα３に対するヒト抗体およびその使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
PT2387583T (pt) 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
GB201512215D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
KR101859576B1 (ko) * 2016-06-30 2018-05-18 가톨릭대학교 산학협력단 Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도
AU2018336785B2 (en) * 2017-09-20 2022-07-14 Regeneron Pharmaceuticals, Inc. Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546716A (ja) 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ＧＦＲα３抗体
WO2007049624A1 (ja) 2005-10-24 2007-05-03 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
JP2015532647A (ja) 2012-08-22 2015-11-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＧＦＲα３に対するヒト抗体およびその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Giuliana Salvatore et al.，Biochemical and Biophysical Research Communications，2002年，vol. 294，pp. 813-817
Minh Nguyen et al.，Clin Cancer Res，2015年，Vol. 21, No. 24，pp. 5552-5562

Also Published As

Publication number Publication date
IL287067A (en) 2021-12-01
AU2020270966B2 (en) 2025-05-15
CA3134258A1 (en) 2020-10-15
JP7688175B2 (ja) 2025-06-03
US20220185900A1 (en) 2022-06-16
MX2021012335A (es) 2021-11-12
JP2024024114A (ja) 2024-02-21
AU2020270966A1 (en) 2021-10-28
KR20210150509A (ko) 2021-12-10
EP3953390A1 (en) 2022-02-16
WO2020210551A1 (en) 2020-10-15
CN113993898B (zh) 2025-05-27
JP2022527373A (ja) 2022-06-01
JP2025113406A (ja) 2025-08-01
MA55615A (fr) 2022-02-16
CN113993898A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
US10947312B2 (en) Human antibodies to GFRα3 and methods of making thereof
JP7688175B2 (ja) Ｒｅｔを結合するヒト抗体およびその使用方法
CN103917562B (zh) 抗-ErbB3抗体及其用途
CN108137700A (zh) 抗psma抗体、结合psma及cd3的双特异性抗原结合分子及其用途
RU2821548C2 (ru) Человеческие антитела, связывающие ret, и способы их применения
HK1261378A1 (en) Human antibodies to gfr 3 and methods of use thereof
HK1261378B (en) Human antibodies to gfralpha3 and methods of use thereof
HK1206037B (en) Human antibodies to gfr 3 and methods of use thereof
EA053242B1 (ru) СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ РАССТРОЙСТВА, СВЯЗАННОГО С АКТИВНОСТЬЮ ИЛИ ЭКСПРЕССИЕЙ TrkB

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240625